Cargando…
Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes
CONTEXT: Temozolomide (TMZ) is endorsed as the treatment of choice in aggressive or malignant pituitary adenomas. OBJECTIVE: Herein we describe a case of an aggressive prolactinoma that was resistant to TMZ. We performed a literature review of similar nonresponsive, aggressive prolactinomas. METHODS...
Autores principales: | Das, Liza, Rai, Ashutosh, Salunke, Pravin, Ahuja, Chirag Kamal, Sood, Ashwani, Radotra, Bishan Dass, Sood, Ridhi, Korbonits, Márta, Dutta, Pinaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763612/ https://www.ncbi.nlm.nih.gov/pubmed/35059545 http://dx.doi.org/10.1210/jendso/bvab190 |
Ejemplares similares
-
Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas
por: Das, Liza, et al.
Publicado: (2021) -
Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas
por: Rai, Ashutosh, et al.
Publicado: (2021) -
Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence
por: Das, Liza, et al.
Publicado: (2021) -
The outcome of TSHoma from a tertiary care institute in India
por: Dutta, Aditya, et al.
Publicado: (2021) -
Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child
por: Dutta, Pinaki, et al.
Publicado: (2019)